![](https://cdn.mdfoundation.com.au/wp-content/uploads/2023/06/15122558/Carousel-1-1024x465.png)
MDFA is Australia’s largest source of research funding in the field of macular disease outside of government
Read MoreMDFA is Australia’s largest source of research funding in the field of macular disease outside of government
Read MoreComposition and functionality of high-density lipoprotein in age-related macular degeneration and a high-risk disease phenotype
Read MoreRedefining macular disease diagnosis to improve access to emerging therapies
Read MoreInvestigating mitochondrial dysfunction in macular degeneration – towards new treatments and biomarkers
Read MoreEvaluating the potential of hyperspectral imaging for detecting and monitoring geographic atrophy Accurate monitoring of
Read MoreVabysmo is a new treatment for age-related macular degeneration and diabetic macular oedema and is now available on the Pharmaceutical Benefits Scheme (PBS) in Australia
Read MoreMDFA 2022 research update
Read MoreMDFA is committing to macular disease research
Read MoreFaricimab has taken one step closer towards clinics in Australia.
Read More